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Abstract Relapse rate is decreased during pregnancy in
multiple sclerosis (MS). Risk for postpartum relapse is
increased in the first 3 months after delivery. We aimed to
study clinical course of MS around pregnancy, using
clinical as well as self-report scales, including data on
quality of life (QoL), and to identify clinical factors pre-
disposing for postpartum relapse. We performed a pro-
spective, longitudinal study among 35 MS patients and 20
controls. In patients we assessed expanded disability status
scale (EDSS), the Guy’s neurological disability scale
(GNDS) and the multiple sclerosis impact scale 29 (MSIS-
29). In patients and controls we assessed the MOS 36 item
short form health survey questionnaire (SF36), consisting
of eight domains. The previously described surge in
relapses after delivery was also obvious in this study
(p = 0.005). At group level EDSS and MSIS-29 did not
show overt fluctuations over time. The GNDS, however,
improved during the third trimester, compared to the first
trimester (p = 0.003). A concomitant improvement in the
SF36 domains vitality (p \ 0.001) and general health
(p = 0.001) was found in patients. At the final visit, at least
9 months after delivery, no worsening of EDSS, GNDS,
MSIS-29 or SF36 was observed compared with the (for MS,
beneficial) third trimester. Duration of disease, relapses in
the year preceding pregnancy or relapses during pregnancy
were not associated with postpartum relapse. QoL is
improved during pregnancy. Although relapse rate was
increased directly after delivery, in the mid long term after
delivery no adverse effects of pregnancy on MS were found.
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Introduction
The clinical debut of multiple sclerosis (MS) in women is
often during the childbearing years [1]. Factors associated
with family planning are a major concern when having a
chronic disease like MS. Pregnancy has a known amelio-
rating effect on the disease activity [2]. In the third tri-
mester the relapse rate is decreased by around 70%
compared to the year preceding pregnancy. Yet in the first
3 months after delivery, one in every three women has a
relapse [2, 3].
Several questions arise when counselling women with
MS who want to become pregnant. First, the timing of a
postpartum relapse, early after delivery, may unfavourably
influence daily care for the newborn infant. Prediction of a
postpartum relapse would be most helpful in order to
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anticipate on this postpartum relapse. A previous study
showed that the following three clinical factors were found
to be predictive of a postpartum relapse: (1) the number of
relapses in the year preceding pregnancy, (2) the number of
relapses during pregnancy, and (3) the duration of disease
[3]. These findings have not been validated in an inde-
pendent prospective cohort.
Second, the clinical data in the few available studies on
pregnancy and MS are limited to the expanded disability
status scale (EDSS) and relapse rate. No quality of life
(QoL) issues or self report scales were addressed in these
studies. Next to insight in disease course in terms of dis-
ability and attack frequency, also better insight in QoL
during and after pregnancy is necessary to inform women
with MS who want to become pregnant.
Third, it has been shown that the relapse rate declines
after a peak in the first 3 months after delivery. Nine
months after delivery the relapse rate is comparable with
the relapse rate in the year preceding pregnancy. Whether
QoL at that time has improved or worsened is unknown.
The aims of this prospective and longitudinal study were
not only to confirm data on EDSS and relapse rate, but also
to address clinical course and outcome by using clinical
scales as well as self-report scales including QoL param-
eters. Our second goal was to identify or confirm clinical
risk factors predisposing for postpartum relapse.
Materials and methods
Participants and procedures
The Rotterdam Study on Pregnancy in MS was performed
at ErasMS, the MS Centre at Erasmus MC. Ambulant MS
patients, with a relapsing remitting disease course, were
invited to participate. Control patients were recruited from
the out-patient clinic of Obstetrics at the Erasmus MC.
Exclusion criteria for MS patients and controls were
recurrent abortion, hypertension, diabetes mellitus or other
systemic diseases. The study was designed to include
patients preconceptionally, but inclusion was also allowed
during pregnancy. Inclusion of all controls occurred during
the first trimester. All MS patients and controls were seen
at 10–12 weeks and 28–30 weeks of pregnancy, and at
4–8 weeks after delivery. MS patients were also invited at
a time point at least 9 months after delivery, without
clinical infection or recent disease activity.
Data on maternal age, disease duration, and parity were
collected at the first visit. Data on gestational age at delivery,
multiple pregnancy, (pre)eclampsia, delivery, birth weight,
and breastfeeding were collected at the last two visits. Data
on relapse rate before pregnancy, during the three trimesters
of pregnancy, and every 3 months in the first year after
delivery were collected by interview at all these time points.
The Guy’s neurological disability scale (GNDS), multiple
sclerosis impact scale 29 (MSIS-29), and EDSS were
assessed in patients at every visit. Both patients and healthy
controls were asked to evaluate their health related QoL the
month prior to evaluation using the MOS 36 item short form
health survey questionnaire (SF36) at each visit.
This study was approved by the ethics committee of the
Erasmus MC and all participants gave written informed
consent.
Measurements
A relapse was defined as an episode of neurological dis-
turbance for which causative lesions are likely to be
inflammatory and demyelinating in nature and lasting more
than 24 h [4]. Pseudo-relapse, meaning recurrence of pre-
vious signs and symptoms or fever-related worsening, was
not considered as a relapse. Disease duration was measured
from time of diagnosis.
The EDSS is the most widely used scoring system in MS
and consists of findings of the neurological examination
[5]. The EDSS is an ordinal score that ranges from 0.0 (no
disability) to 10.0 (death due to MS). The EDSS was
scored at every visit by trained neurologists (RFN, TAMS,
IAH, IAK, NJ, and RQH).
The GNDS consists of 12 items, all generating a score
ranging from 0 (optimal health) to 5 (poor health) with a
summed maximum total score of 60 [6]. Items are cogni-
tion, mood, vision, speech, swallowing, lower and upper
extremity function, bladder and bowel function, sexual
function, fatigue, and one free item addressing another
problem not yet contained in other items.
The MSIS-29 is a validated self-report scale consisting
of two domains: physical health (20 items) and mental
health (nine items) [7–9]. Both domains generate a score
ranging from 0 (optimal health) to 100 (poor health). The
questions reflected on the 2 weeks preceding evaluation.
The SF36 is an instrument comprising four physical
health domains and four mental health domains and has
been used before in MS patients [10–12]. The physical
health domains are physical functioning, role physical
functioning, bodily pain, and general health. The four
mental health domains are social functioning, vitality, role
emotional functioning, and mental health. For each domain
a score is generated ranging from 0 (poor health) to 100
(optimal health).
Statistical analysis
Differences in demographic and pregnancy characteristics
and the SF36 between patients and healthy women were
compared using the Student’s t test or Mann–Whitney U test
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for continuous variables and chi-square for categorical
variables. The same statistics were used for comparing
characteristics of MS patients with and without a postpartum
relapse. Relapse rate, clinical scales and self-report scales at
the different time points were compared to the third trimester
using a multiple measurements linear mixed model analysis.
The third trimester was used as reference because maximal
disease amelioration has been reported before at that time
point [2]. A p-value below 0.01 was considered significant.
Data were analyzed using SPSS version 16.0.
Results
Characteristics of the study population
Thirty-five women with MS and 20 controls participated in
this study. Eighteen MS patients were included before
pregnancy, 16 during the first trimester, and one during the
third trimester. The mean time from inclusion to pregnancy
in the 18 MS patients was 6 [standard deviation (SD):
±3.9, range 1–20] months. The mean time from delivery to
the final visit in the MS group was 10 (SD: ±3.5, range
8–24) months. All controls were enrolled in the first tri-
mester of pregnancy.
The controls were recruited from the outpatient clinic of
Obstetrics in our hospital. The reasons for their referral were:
previous cesarean section (six), history of cardiac problems
(three, of which one also had twin pregnancy), medically
assisted pregnancy (two), prematurity in previous pregnancy
(two), previous post-natal depression (one), uterus duplex
(one), epilepsy (one), twin pregnancy (one), metabolic dis-
order (one). Two women had no specific medical indication.
In the MS patients median disease duration was 4.0 (SD:
±4.0, range 0–13) years. Median EDSS was 1.5 (SD: ±0.8,
range 0–4.0) in the first trimester (n = 34). Three MS
patients received intravenous immunoglobulins directly
after delivery with the aim to prevent possible relapses
[13]. One woman had already received corticosteroids as
treatment for a postpartum relapse at the time of her first
postpartum visit. At time of the final visit four patients used
immune modulating drugs.
Data on pregnancy and birth outcome are presented in
Table 1. A smaller proportion of women were nulliparous
in the control group, compared to the MS patients.
Breastfeeding at time of the first postpartum visit was more
frequently observed in the MS group, compared to the
control group.
Annualized relapse rate
The annualized relapse rate is depicted in Fig. 1. After
delivery a significantly increased relapse rate was observed
during the first 3 months after delivery compared to the
third trimester (p = 0.005). There was no significant dif-
ference in the annualized relapse rate in the year preceding
pregnancy compared to the period 9–12 months after
delivery.
MS specific clinical and self report scales
The MS specific clinical and self report scales are shown in
Fig. 2. The GNDS showed a significant drop during the
Table 1 Maternal age and data on pregnancy and birth outcome
Patients Controls
N = 35 N = 20
Maternal age (±SD) (years) 31.2 (±3.8) 31.3 (±4.6)
Nulliparous (%) 71 35
Cesarean section (%) 14 25
Assisted vaginal delivery (forceps/
vacuum) (%)
11 5
Multiple (twin) pregnancy (%) 0 10
Gestational age at delivery (±SD)
(weeks)
39.2 (±1.5) 38.1 (±2.7)
Prematurity (\37 weeks of gestation)a
(%)
6 5
Birth weight (±SD) (grams)a 3,329
(±354)
3,496
(±686)
Small for gestational ageb (%) 0 0
Breast feeding (%) 69 40
(pre)eclampsia (%) 0 0
MS Multiple Sclerosis, SD standard deviation
a Not including twin pregnancy
b Small for gestational age is defined as birth weight under -2SD,
using standardized intrauterine growth charts
Fig. 1 Relapse rate: before, during and after pregnancy in MS
patients. Values represent the mean (±95% CI) annualized relapse
rate. The third trimester was used as reference. *P-value \0.01. PP
postpartum
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third trimester compared to the first trimester (p = 0.003)
and the first postpartum visit (p = 0.001). We observed
that about 85% of the mean drop in GNDS was mainly
explained by three of the 12 items. These items concerned
sexuality (31%), fatigue (28%), and a free item in which a
complaint could be issued that was not addressed before in
the other eleven items of the GNDS (26%). No differences
were observed in the two domains of the MSIS-29 or the
EDSS during the study.
Quality of life
The SF36 was measured in both healthy controls and MS
patients. The eight domains of the SF36 are shown in
Fig. 3. MS patients reported an improvement in general
health and in vitality during the third trimester compared to
the first trimester (respectively, p = 0.001 and p \ 0.001).
Healthy women reported an evident and significant
increase in bodily pain at time of the first postpartum visit
(p = 0.002) compared to the first trimester. The controls
reported significantly more bodily pain than MS patients
during the third trimester (p \ 0.001). A significant
decrease in physical functioning in MS patients was found
during the third trimester, compared to the first trimester
(p = 0.002). Physical functioning improved significantly
after delivery in both MS patients (p \ 0.001) and healthy
women (p \ 0.001). Role physical functioning was
decreased in the controls during the third trimester
compared the first postpartum visit (p = 0.009). No dif-
ferences were found in the domains social functioning, role
emotional functioning and mental health.
Postpartum relapse
Postpartum relapse occurred in 10 out of 35 MS patients
(29%). One out of the three women treated with intrave-
nous immunoglobulins after delivery had a postpartum
relapse. The differences between the patients with and
without a postpartum relapse are shown in Table 2.
Women with a relapse during pregnancy were more likely
to also experience a relapse after delivery. This difference
was not significant. At the final visit, we found no differ-
ences in all assessment instruments, between patients with
and without a postpartum relapse. Both groups also showed
no differences in all assessment instruments comparing
their third trimester visit with their final visit.
Discussion
We here present prospective and longitudinal data on
clinical and QoL parameters during pregnancy in MS. We
found an increase in relapse rate after delivery, comparable
with previous studies [2, 3, 14]. We observed that this
increase in relapse rate directly after delivery did not cause
sustained adverse effects of pregnancy on MS in all used
Fig. 2 EDSS, GNDS and
MSIS29 scores: before, during
and after pregnancy in MS.
Values represent mean (±95%
CI) scores of the EDSS, GNDS,
MSIS-29 (physical and
psychological subscale). The
third trimester was used as
reference. *P \ 0.01. PP
postpartum, EDSS expanded
disability status scale, GNDS
Guy’s neurological disability
scale, MSIS-29 multiple
sclerosis impact scale 29
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instruments at time of the final visit, 9 months or more
after delivery.
During pregnancy and after delivery we observed no
difference in the MS specific assessment instruments EDSS
and the self report scale MSIS-29. A small improvement in
the GNDS was observed during the third trimester.
Remarkably, this improvement in the GNDS was mainly
explained by the domains concerning sexuality, fatigue, and
Fig. 3 SF36 subscale scores: before, during and after pregnancy in
MS and healthy women. Values represent mean (±95% CI) scores on
the eight subscales of the SF36: physical functioning, role physical
functioning, bodily pain, general health, vitality, social functioning,
role emotional functioning and mental health. The third trimester was
used as reference. Scores range from 0 = poor health to 100 = opti-
mal health. *P-value\0.01, **P-value\0.001, PP postpartum, SF36
MOS 36 item short form health survey questionnaire
Table 2 Characteristics of
patients with and without
postpartum relapse
SD standard deviation, PP
postpartum, IQR interquartile
range, EDSS expanded
disability status scale
PP relapse No PP relapse P value
N = 10 N = 25
Maternal age (±SD) (years) 31.1 (±4.5) 31.3 (±3.6) 0.76
Disease duration (±SD) (years) 2.9 (±2.0) 5.0 (±4.5) 0.36
Relapse in year before pregnancy (%) 50 44 1.0
Relapse during pregnancy (%) 30 8 0.13
Nulliparous (%) 70 72 1.0
Median EDSS first trimester (IQR) 2.0 (1.5–2.13) 1.25 (1.0–1.88) 0.01
Assisted vaginal delivery or cesarean section (%) 30 24 1.0
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the free item. Much in line with the decrease in fatigue is the
improvement in the SF36 domains vitality and general health
in MS patients during the third trimester. Contradictory to the
amelioration of MS in the third trimester is the decreased
health in the SF36 domain physical functioning in MS
patients during the third trimester, compared with the first
trimester and the first postpartum visit. On the other hand,
decreased health in the SF36 domain physical functioning
was also observed in controls during the third trimester
compared to the postpartum visit. Therefore, this may be
explained as a pregnancy effect and not MS related.
We also set out to validate several clinical risk factors
for postpartum relapse that were previously identified [3].
These were disease duration, number of relapses in the year
preceding pregnancy and number of relapses during preg-
nancy. We were not able to validate these findings in our
cohort. We did observe that women with a relapse during
pregnancy more likely also had a postpartum relapse,
although this was not significant. It is possible that our
numbers were too small to demonstrate such effects.
Interestingly, a recent study showed that exclusive breast-
feeding was associated with a smaller chance of post-
partum relapse [17]. We and others could not reproduce
these intriguing findings [2, 3, 14, 18, 19]. Taken together,
we can conclude that, until now, there are no good clinical
parameters predicting postpartum relapse. We, therefore,
are in need of reliable biomarkers, able to predict a post-
partum relapse. Interleukin 8 may be a candidate [20].
As described before [15, 16], we recorded no major
adverse effects on birth outcome. A higher proportion of
neonates small for gestational age in mothers with MS has
been reported [15]. We also found a lower birth weight in
the MS group, but this did not reach statistical significance.
Three points should be taken into account in respect to
our data. First, the small numbers of patients and controls
limited the conclusions of our study. We were not able to
test for interaction effects and related measurements. In
order not to make an over-interpretation we considered
p-values under 0.01 to be significant and we used one visit
as main reference. We chose the third trimester as main
reference because maximal disease amelioration was
reported at that time point [2, 3].
Second, the controls were referred to the outpatient
clinic of Obstetrics mainly because of complications in
previous pregnancies. Therefore, the chance of complica-
tions in the controls during these studied pregnancies and
deliveries was increased. This may have influenced preg-
nancy outcome and QoL of the controls during and after
pregnancy. It may likely explain why the controls reported
more bodily pain than the women with MS during the third
trimester.
Third, the participating patients in our study had a low
EDSS, likely because we selected patients with a child
wish. This low disability may have caused floor or ceiling
effects limiting the ability of our measurement instruments
to detect change. Especially the SF36 is sensitive to floor
and ceiling effects [21]. It is possible that subtle differences
in QoL were not detected by the SF36.
We can conclude that in the mid-long term after preg-
nancy in MS patients EDSS, GNDS, MSIS-29, relapse rate
and QoL are not unfavourably altered. We also showed that
amelioration of disease course during pregnancy is not only
defined by a decreasing relapse rate, but can also be
regarded in terms of QoL, mostly appreciated in the SF36
domains vitality and general health. This underlines the
necessity for including assessments of QoL when deter-
mining MS disease severity. The results from this study
will help neurologists and MS-nurses counselling pregnant
MS patients or MS patients with a child wish.
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